IL-6 specific monoclonal antibodies, hybridomas therefor and methods of making and using same

• US 5,618,700 A
• Filed: 11/14/1989
• Issued: 04/08/1997
• Est. Priority Date: 11/14/1988
• Status: Expired due to Term

• Current Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Original Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Inventors: Hadas, Eran, Rubinstein, Menachem, Novick, Daniela, Revel, Michel, Mory, Yves
• Primary Examiner(s): Hutzell, Paula K.
• Application Number:
  US07/436,321
• Time in Patent Office: 2,702 Days
• Field of Search: 530/387, 530/413, 530/388.23, 435/240.27, 435/70.21, 436/172.2, 436/548
• US Class Current: 435/70.21
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/31 from Staphylococcus (G)
• CPC Class Codes: C07K 14/5412 IL-6
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/705 containing a protein-A fusion
• CPC Class Codes: C07K 2319/75 containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

The hybridoma 34-1 (CNCM I-813) which produces anti-human IL-6 monoclonal antibody 34-1 is disclosed. Methods of producing the monoclonal antibody and methods for affinity purification of human IL-6 using monoclonal antibody 34-1 are also described.

Claims

1. The hybridoma cell line CNCM I-813 (No. 34-1).

2. A monoclonal antibody expressible by hybridoma cell line CNCM I-813 (HB2 34-1).

5. A method for the immunopurification of human biologically active IL-6 comprising passing a sample containing human IL-6 through an immunoadsorbent column comprising a monoclonal antibody in accordance with claim 2 bound to a solid phase support, washing the column, and eluting IL-6 from the column.

3. A method for producing anti-IL-6 monoclonal antibodies which comprises culturing hybridoma CNCM I-813 in a suitable growth medium and recovering the monoclonal antibodies from the supernatant of said hybridoma.

4. A method for producing anti-IL-6 monoclonal antibodies which comprises injecting hybridoma CNCM I-813 in a mouse and recovering the monoclonal antibodies from the ascitic fluid of said mouse.